NIKKEI 225
33,231.27 +455.45 (+1.39%) HANG SENG
16,327.86 0.00 (0.00%) CRUDE OIL
72.37 +0.05 (+0.07%) GOLD FUTURES
2,038.60 +2.30 (+0.11%) DOW
36,124.56 -79.88 (-0.22%) Bitcoin GBP
34,935.05 +1,819.95 (+5.50%)
Evotec SE (0IRF.IL)
| Previous close | 18.14 |
| Open | 0.00 |
| Bid | 17.93 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 173,245 |
| Market cap | 3.573B |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.58 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Evotec SE's (ETR:EVT) largest shareholders are individual investors with 47% ownership, institutions own 34%
Key Insights The considerable ownership by individual investors in Evotec indicates that they collectively have a...
Insider MonkeyEvotec SE (NASDAQ:EVO) Q3 2023 Earnings Call Transcript
Evotec SE (NASDAQ:EVO) Q3 2023 Earnings Call Transcript November 11, 2023 Werner Lanthaler: Welcome to our — good morning. Good afternoon. Welcome to our Q3 Call. Resilient into the Future of Biopharma R&D. That’s how we titled this presentation, which we have uploaded to the Internet and you are welcome to join this call also […]
GlobeNewswireDewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORMAGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILESTONE AND ROYALTY PAYMENTS TO EVOTEC BASED ON SUCCESS OF OVERALL PROGRAMS HAMBURG, Germany and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) an
